Literature DB >> 17395906

Acute coronary syndrome.

A Khavandi, P R Walker.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17395906      PMCID： PMC1839238          DOI： 10.1136/bmj.39149.369329.80

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  9 in total

Review 1.  A critical appraisal of platelet glycoprotein IIb/IIIa inhibition.

Authors:  D P Chew; D J Moliterno
Journal:  J Am Coll Cardiol       Date:  2000-12       Impact factor: 24.094

Review 2.  The use of glycoprotein IIb/IIIa inhibitors in patients with coronary artery disease.

Authors:  M S Sabatine; I K Jang
Journal:  Am J Med       Date:  2000-08-15       Impact factor: 4.965

3.  Management of non-ST-elevation acute coronary syndromes: how cost-effective are glycoprotein IIb/IIIA antagonists in the UK National Health Service?

Authors:  Stephen Palmer; Mark Sculpher; Zoe Philips; Mike Robinson; Laura Ginnelly; Ameet Bakhai; Keith Abrams; Nicola Cooper; Chris Packham; Khaled Alfakih; Alistair Hall; David Gray
Journal:  Int J Cardiol       Date:  2005-04-20       Impact factor: 4.164

4.  Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials.

Authors:  Eric Boersma; Robert A Harrington; David J Moliterno; Harvey White; Pierre Théroux; Frans Van de Werf; Anneke de Torbal; Paul W Armstrong; Lars C Wallentin; Robert G Wilcox; John Simes; Robert M Califf; Eric J Topol; Maarten L Simoons
Journal:  Lancet       Date:  2002-01-19       Impact factor: 79.321

5.  Impact of specialty of admitting physician and type of hospital on care and outcome for myocardial infarction in England and Wales during 2004-5: observational study.

Authors:  John S Birkhead; Clive Weston; Derek Lowe
Journal:  BMJ       Date:  2006-05-16

6.  Correlation between the TIMI risk score and high-risk angiographic findings in non-ST-elevation acute coronary syndromes: observations from the Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) trial.

Authors:  Jessica L Mega; David A Morrow; Marc S Sabatine; Xue-Qiao Zhao; Steven M Snapinn; Peter M DiBattiste; C Michael Gibson; Elliott M Antman; Eugene Braunwald; Pierre Théroux
Journal:  Am Heart J       Date:  2005-05       Impact factor: 4.749

7.  Early use of glycoprotein IIb/IIIa inhibitors in non-ST-elevation acute myocardial infarction: observations from the National Registry of Myocardial Infarction 4.

Authors:  Eric D Peterson; Charles V Pollack; Matthew T Roe; Lori S Parsons; Katherine A Littrell; John G Canto; Hal V Barron
Journal:  J Am Coll Cardiol       Date:  2003-07-02       Impact factor: 24.094

8.  Usefulness of tirofiban among patients treated without percutaneous coronary intervention (TIMI high risk patients in PRISM-PLUS).

Authors:  David A Morrow; Marc S Sabatine; Elliott M Antman; Christopher P Cannon; Eugene Braunwald; Pierre Theroux
Journal:  Am J Cardiol       Date:  2004-09-15       Impact factor: 2.778

9.  ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--2002: summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina).

Authors:  Eugene Braunwald; Elliott M Antman; John W Beasley; Robert M Califf; Melvin D Cheitlin; Judith S Hochman; Robert H Jones; Dean Kereiakes; Joel Kupersmith; Thomas N Levin; Carl J Pepine; John W Schaeffer; Earl E Smith; David E Steward; Pierre Theroux; Raymond J Gibbons; Joseph S Alpert; David P Faxon; Valentin Fuster; Gabriel Gregoratos; Loren F Hiratzka; Alice K Jacobs; Sidney C Smith
Journal:  Circulation       Date:  2002-10-01       Impact factor: 29.690
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.